Researchers report a hazard ratio of 0.717 versus lifestyle changes in TriNetX records, while stressing the observational data can't prove the drug prevents cancer.
Recap by typeshit. Full story at BIOENGINEER.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Researchers think orexin drugs could expand into ADHD and fatigue the way GLP-1s grew past diabetes. Alkermes reported early ADHD results in 50 adults.
A Facebook clip has a doctor explaining concerns about muscle loss and hair thinning in people taking GLP-1 medications.
Loading…